<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241203072141&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241203072141&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 03 Dec 2024 12:21:42 +0000</lastbuilddate>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3. doi: 10.1161/CIR.0000000000001293. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine products has transformed since the last American Heart Association smokeless tobacco policy statement. Several varieties of tobacco-free oral nicotine products-including oral nicotine pouches; nontherapeutic nicotine gums, lozenges, and tablets; and nicotine gummies-have rapidly proliferated. The sales of oral nicotine pouches, in particular, have increased substantially; however, no data are available on their cardiovascular or health risks. In addition, synthetic (compared with tobacco-derived) nicotine has been used in some brands of oral nicotine products, but its cardiovascular and health effects have been inadequately studied. Robust public policy levers are identified to support ending addiction to all commercial tobacco products. Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39624904</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001293>10.1161/CIR.0000000000001293</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39624904</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Cheryl R Dennison Himmelfarb</dc:creator>
<dc:creator>Neal L Benowitz</dc:creator>
<dc:creator>Melissa D Blank</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Paul J Chase</dc:creator>
<dc:creator>Esa M Davis</dc:creator>
<dc:creator>Jessica L Fetterman</dc:creator>
<dc:creator>Brittney Keller-Hamilton</dc:creator>
<dc:creator>Oluwabunmi Ogungbe</dc:creator>
<dc:creator>Robert L Page</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Rose Marie Robertson</dc:creator>
<dc:creator>Laurie P Whitsel</dc:creator>
<dc:creator>American Heart Association Advocacy Coordinating Committee</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39624904</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001293</dc:identifier>
</item>
<item>
<title>Long-QT Trafficking Map</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1882-1884. doi: 10.1161/CIRCULATIONAHA.124.072169. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621763</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072169>10.1161/CIRCULATIONAHA.124.072169</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621763</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Barry London</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-QT Trafficking Map</dc:title>
<dc:identifier>pmid:39621763</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072169</dc:identifier>
</item>
<item>
<title>In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621762/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>Conventional forms of noninvasive cardiovascular imaging that evaluate morphology, function, flow, and metabolism play a vital role in individual treatment decisions, often based on guidelines. Innovations in molecular imaging have enhanced our ability to spatially quantify the expression of a wider array of disease-related proteins, genes, or cell types, or the activity of specific pathogenic pathways. These techniques, which usually rely on design of targeted imaging probes, have already been...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1885-1897. doi: 10.1161/CIRCULATIONAHA.124.066522. Epub 2024 Dec 2.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Conventional forms of noninvasive cardiovascular imaging that evaluate morphology, function, flow, and metabolism play a vital role in individual treatment decisions, often based on guidelines. Innovations in molecular imaging have enhanced our ability to spatially quantify the expression of a wider array of disease-related proteins, genes, or cell types, or the activity of specific pathogenic pathways. These techniques, which usually rely on design of targeted imaging probes, have already been used extensively in cancer medicine and have now become part of cardiovascular care in conditions such as amyloidosis and sarcoidosis. The recognition that common cardiovascular conditions are caused by a substantial diversity of pathobiologic pathways and the diversity of therapies available for use have rekindled interest in expanding the role of molecular imaging of tissue phenotype to improve precision in diagnosis and therapeutic decision-making. The intent of this article is to raise awareness and understanding of approaches to molecular or cellular imaging of phenotype with targeted probes, and their potential to promote the principles of precision medicine. Also addressed are the diverse roles of molecular imaging to improve precision and efficiency of new drug development at the stages of candidate identification, preclinical testing, and clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621762/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621762</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.066522>10.1161/CIRCULATIONAHA.124.066522</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621762</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan R Lindner</dc:creator>
<dc:creator>Matteo Morello</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development</dc:title>
<dc:identifier>pmid:39621762</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.066522</dc:identifier>
</item>
<item>
<title>Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621761/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):e468. doi: 10.1161/CIRCULATIONAHA.124.070892. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621761/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621761</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070892>10.1161/CIRCULATIONAHA.124.070892</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621761</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Xinyue Yang</dc:creator>
<dc:creator>Zhiqiang Zhang</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Yang and Zhang Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</dc:title>
<dc:identifier>pmid:39621761</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070892</dc:identifier>
</item>
<item>
<title>Echocardiography, the AHA, and 100 Years</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1819-1822. doi: 10.1161/CIRCULATIONAHA.124.066991. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621760</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.066991>10.1161/CIRCULATIONAHA.124.066991</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621760</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Joseph Kisslo</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Echocardiography, the AHA, and 100 Years</dc:title>
<dc:identifier>pmid:39621760</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.066991</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1898-1903. doi: 10.1161/CIRCULATIONAHA.124.072974. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621759</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072974>10.1161/CIRCULATIONAHA.124.072974</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621759</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:39621759</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072974</dc:identifier>
</item>
<item>
<title>Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):e469-e470. doi: 10.1161/CIRCULATIONAHA.124.071539. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621758</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071539>10.1161/CIRCULATIONAHA.124.071539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621758</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Reply by Sandhu et al to Letter Regarding Article, "Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial"</dc:title>
<dc:identifier>pmid:39621758</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071539</dc:identifier>
</item>
<item>
<title>Pitfalls of Choosing a Study End Point Including Cardiovascular Death in Comparative Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621757/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1823-1825. doi: 10.1161/CIRCULATIONAHA.124.070899. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621757/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39621757</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070899>10.1161/CIRCULATIONAHA.124.070899</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621757</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Stephanie Armbruster</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Lee-Jen Wei</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Pitfalls of Choosing a Study End Point Including Cardiovascular Death in Comparative Clinical Trials</dc:title>
<dc:identifier>pmid:39621757</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070899</dc:identifier>
</item>
<item>
<title>Data science from EuroHeart: a job in hand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae819. doi: 10.1093/eurheartj/ehae819. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39612912/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39612912</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae819>10.1093/eurheartj/ehae819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39612912</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Adam Timmis</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Data science from EuroHeart: a job in hand</dc:title>
<dc:identifier>pmid:39612912</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae819</dc:identifier>
</item>
<item>
<title>Proteolethargy is a pathogenic mechanism in chronic disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 25:S0092-8674(24)01274-1. doi: 10.1016/j.cell.2024.10.051. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pathogenic mechanisms of many diseases are well understood at the molecular level, but there are prevalent syndromes associated with pathogenic signaling, such as diabetes and chronic inflammation, where our understanding is more limited. Here, we report that pathogenic signaling suppresses the mobility of a spectrum of proteins that play essential roles in cellular functions known to be dysregulated in these chronic diseases. The reduced protein mobility, which we call proteolethargy, was linked to cysteine residues in the affected proteins and signaling-related increases in excess reactive oxygen species. Diverse pathogenic stimuli, including hyperglycemia, dyslipidemia, and inflammation, produce similar reduced protein mobility phenotypes. We propose that proteolethargy is an overlooked cellular mechanism that may account for various pathogenic features of diverse chronic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39610243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39610243</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.051>10.1016/j.cell.2024.10.051</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39610243</guid>
<pubDate>Fri, 29 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Alessandra Dall'Agnese</dc:creator>
<dc:creator>Ming M Zheng</dc:creator>
<dc:creator>Shannon Moreno</dc:creator>
<dc:creator>Jesse M Platt</dc:creator>
<dc:creator>An T Hoang</dc:creator>
<dc:creator>Deepti Kannan</dc:creator>
<dc:creator>Giuseppe Dall'Agnese</dc:creator>
<dc:creator>Kalon J Overholt</dc:creator>
<dc:creator>Ido Sagi</dc:creator>
<dc:creator>Nancy M Hannett</dc:creator>
<dc:creator>Hailey Erb</dc:creator>
<dc:creator>Olivia Corradin</dc:creator>
<dc:creator>Arup K Chakraborty</dc:creator>
<dc:creator>Tong Ihn Lee</dc:creator>
<dc:creator>Richard A Young</dc:creator>
<dc:date>2024-11-29</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Proteolethargy is a pathogenic mechanism in chronic disease</dc:title>
<dc:identifier>pmid:39610243</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.051</dc:identifier>
</item>
<item>
<title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae623. doi: 10.1093/eurheartj/ehae623. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607800</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae623>10.1093/eurheartj/ehae623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607800</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Angelo Oliva</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Handle with care, proceed with caution: do frail patients presenting with acute coronary syndrome benefit from revascularization?</dc:title>
<dc:identifier>pmid:39607800</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae623</dc:identifier>
</item>
<item>
<title>Acetylation alchemy: how Nat10 shapes vascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae822. doi: 10.1093/eurheartj/ehae822. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae822>10.1093/eurheartj/ehae822</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607798</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Timothy Warwick</dc:creator>
<dc:creator>Leo Kurian</dc:creator>
<dc:creator>Ralf P Brandes</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acetylation alchemy: how Nat10 shapes vascular health</dc:title>
<dc:identifier>pmid:39607798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae822</dc:identifier>
</item>
<item>
<title>Thoracic aortic disease: why sex matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae713. doi: 10.1093/eurheartj/ehae713. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607796/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607796</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae713>10.1093/eurheartj/ehae713</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607796</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Julia Dumfarth</dc:creator>
<dc:creator>Simone Gasser</dc:creator>
<dc:creator>Michael Grimm</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Thoracic aortic disease: why sex matters</dc:title>
<dc:identifier>pmid:39607796</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae713</dc:identifier>
</item>
<item>
<title>Pregnancy-related aortic pathology: where do we go from here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae697. doi: 10.1093/eurheartj/ehae697. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607795</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae697>10.1093/eurheartj/ehae697</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607795</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Johanna A van der Zande</dc:creator>
<dc:creator>Mark R Johnson</dc:creator>
<dc:creator>Jolien W Roos-Hesselink</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pregnancy-related aortic pathology: where do we go from here?</dc:title>
<dc:identifier>pmid:39607795</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae697</dc:identifier>
</item>
<item>
<title>Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae489. doi: 10.1093/eurheartj/ehae489. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae489>10.1093/eurheartj/ehae489</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607792</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Elisa Duregotti</dc:creator>
<dc:creator>Manuel Mayr</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dissecting the effect of genetic variants on atherosclerosis: integrating bulk and single-cell transcriptomics</dc:title>
<dc:identifier>pmid:39607792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae489</dc:identifier>
</item>
<item>
<title>Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae820. doi: 10.1093/eurheartj/ehae820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae820>10.1093/eurheartj/ehae820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607783</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Magnus Bäck</dc:creator>
<dc:creator>Robin Hofmann</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial infarction and low ambient temperature: does presence or absence of stenoses make a difference?</dc:title>
<dc:identifier>pmid:39607783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae820</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Three is better than one for long-term risk prediction in healthy women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39607765/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 28:ehae813. doi: 10.1093/eurheartj/ehae813. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39607765/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39607765</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae813>10.1093/eurheartj/ehae813</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39607765</guid>
<pubDate>Thu, 28 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Leonarda Galiuto</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-11-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Three is better than one for long-term risk prediction in healthy women</dc:title>
<dc:identifier>pmid:39607765</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae813</dc:identifier>
</item>
<item>
<title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2305-2307. doi: 10.1016/j.jacc.2024.07.063.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39603751</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.063>10.1016/j.jacc.2024.07.063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603751</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Brad Spellberg</dc:creator>
<dc:creator>Todd C Lee</dc:creator>
<dc:creator>Bassam Ghanem</dc:creator>
<dc:creator>Emily G McDonald</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Endocarditis Therapy: The Move From Expert Opinion to Evidence</dc:title>
<dc:identifier>pmid:39603751</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.063</dc:identifier>
</item>
<item>
<title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2293-2304. doi: 10.1016/j.jacc.2024.06.053.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The results from the POET (Partial Oral Treatment of left-sided Endocarditis) trial were published in August 2018 and established noninferiority of oral step-down antibiotic treatment in stabilized patients with infective endocarditis (IE). Data on length of hospital stay (LOS) and safety following the POET trial are warranted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to examine changes in LOS and safety (mortality and relapse of bacteremia) before and after POET publication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using Danish nationwide registries, patients with first-time IE caused by Streptococcus spp., Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci from 2012 to 2021 were identified. Median LOS was examined according to publication date (before and after September 2018). Mortality and relapse of bacteremia at 180 days of follow-up were examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 3,008 patients before POET publication (median age 72.8 years) and 1,740 after publication (median age 75.2 years) (P &lt; 0.0001). The median LOS decreased by 8 days: 41 days (Q1-Q3: 29-49 days) before POET publication and 33 days (Q1-Q3: 21-44 days) after POET publication (P &lt; 0.0001). Similar reductions in LOS were seen across microbiological etiologies and age groups. Reduction in LOS was most pronounced in nonsurgically treated patients. Mortality from IE admission to a maximum of 180 days' follow-up was 27.5% before POET publication and 28.3% after publication (P = 0.41). The bacteremia relapse rate within 180 days was 3.5% before POET publication and 1.6% after publication (P = 0.0002).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Following the POET trial, we found a reduction in median LOS of 8 days with no change in mortality and an associated lower rate of relapse of bacteremia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39603750</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.053>10.1016/j.jacc.2024.06.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603750</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lauge Østergaard</dc:creator>
<dc:creator>Mia Marie Pries-Heje</dc:creator>
<dc:creator>Marianne Voldstedlund</dc:creator>
<dc:creator>Niels Eske Bruun</dc:creator>
<dc:creator>Jonas Agerlund Povlsen</dc:creator>
<dc:creator>Nana Køber</dc:creator>
<dc:creator>Nikolaj Ihlemann</dc:creator>
<dc:creator>Christian Tuxen</dc:creator>
<dc:creator>Rasmus Hasselbalch</dc:creator>
<dc:creator>Peter Godsk Jørgensen</dc:creator>
<dc:creator>Anna Stahl</dc:creator>
<dc:creator>Eva Havers-Borgersen</dc:creator>
<dc:creator>Jeppe Kofoed Petersen</dc:creator>
<dc:creator>Claus Moser</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Emil Loldrup Fosbøl</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Length of Hospital Stay for Endocarditis Before and After the Partial Oral Treatment of Endocarditis Trial</dc:title>
<dc:identifier>pmid:39603750</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.053</dc:identifier>
</item>
<item>
<title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2290-2292. doi: 10.1016/j.jacc.2024.07.064.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39603749</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.064>10.1016/j.jacc.2024.07.064</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603749</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Márton Tokodi</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Should We Let AI-ECG Algorithms Take Over the Grading of Diastolic Dysfunction in Mitral Regurgitation?</dc:title>
<dc:identifier>pmid:39603749</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.064</dc:identifier>
</item>
<item>
<title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241203072141&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3;84(23):2278-2289. doi: 10.1016/j.jacc.2024.06.054.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The determination of left ventricular diastolic function (LVDF) in patients with significant (≥moderate) mitral regurgitation (MR) poses a complex challenge. We recently validated an artificial intelligence-enabled electrocardiogram (AI-ECG) algorithm to estimate LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the risk of all-cause mortality across AI-ECG LVDF-derived myocardial disease (MD) grades in MR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective study including all patients in the AI-ECG LVDF study testing group who underwent comprehensive transthoracic echocardiography confirming significant MR and electrocardiogram within 14 days of each other at the Mayo Clinic between September 2001 and April 2023. AI-ECG LVDF status was determined based on the index electrocardiogram and used to categorize patients into 3 stages of MD: MD-1, normal or grade 1 LVDF; MD-2, grade 2 LVDF; and MD-3, grade 3 LVDF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,019 patients with significant MR (mean age 69.8 years; 49.0% women), 1,175 (29.2%), 1,881 (46.8%), and 963 (24.0%) were classified by AI-ECG as MD-1, MD-2, and MD-3, respectively. The median mitral effective regurgitant orifice area was 26 mm<sup>2</sup> (Q1-Q3: 20-36 mm<sup>2</sup>). Over a median follow-up of 3.5 years, 1,636 (40.7%) patients died. In multivariable survival analysis adjusted for multiple risk factors, a higher diastolic function grade was independently associated with an increased death risk (MD-2, adjusted HR [aHR]: 1.99; 95% CI: 1.62-2.45; MD-3, aHR: 2.65; 95% CI: 2.11-3.34). These findings were consistent when accounting for mitral valve intervention and across various sensitivity and subgroup analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with significant MR, the grading of LVDF by AI-ECG is independently associated with all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39603748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241203072141&v=2.18.0.post9+e462414">39603748</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.054>10.1016/j.jacc.2024.06.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39603748</guid>
<pubDate>Wed, 27 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gal Tsaban</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Samual Wopperer</dc:creator>
<dc:creator>Muhannad Abbasi</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Garvan C Kane</dc:creator>
<dc:creator>Francisco Lopez-Jimenez</dc:creator>
<dc:creator>Sorin V Pislaru</dc:creator>
<dc:creator>Vuyisile T Nkomo</dc:creator>
<dc:creator>Abhishek J Deshmukh</dc:creator>
<dc:creator>Samuel J Asirvatham</dc:creator>
<dc:creator>Peter A Noseworthy</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:creator>Zachi Attia</dc:creator>
<dc:creator>Jae K Oh</dc:creator>
<dc:date>2024-11-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Using Electrocardiogram to Assess Diastolic Function and Prognosis in Mitral Regurgitation</dc:title>
<dc:identifier>pmid:39603748</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.054</dc:identifier>
</item>





























</channel>
</rss>